Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the challenges and treatment options for pancreatic cancer, emphasizing the need for a collaborative care approach due to the disease's advanced presentation and poor prognosis; it reports no new clinical findings.

This study found that PC 3DP models are reliable preclinical tools that could potentially customize treatment strategies and predict patient prognoses by correlating drug sensitivity profiles with clinical outcomes, though larger patient cohort validation is needed to confirm clinical utility.

This study observed that pancreatic cancer-related skin lesions in mice are linked to microbiota imbalances, specifically noting changes in the abundance of certain bacterial genera, which may offer potential diagnostic or therapeutic targets for managing skin complications in humans with pancreatic cancer.

This article reviews the symptoms and diagnostic challenges of pancreatic cancer and reports no new clinical findings, emphasizing the common presentation of jaundice, anorexia, nausea, and depression in patients.

This study observed that female pancreatic cancer patients were more likely to experience specific chemotherapy side effects, while younger patients generally faced lower toxicity risks.

This review critically examines recent progress in peptide-based treatments for pancreatic disorders, including tools and strategies for pancreatitis, diabetes, and pancreatic cancer, highlighting advancements in drug design and preclinical efficacy, while also detailing ongoing clinical trials and future directions in precision medicine.

This study discusses a rare case of subacute cutaneous lupus erythematosus induced by nab-paclitaxel, a complication scarcely reported in existing literature related to paclitaxel use.

This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.

This study reports a new family with hereditary fibrosing poikiloderma (POIKTMP) and identifies a pancreatic cancer occurrence in a family member, raising questions about FAM111B's role as a potential cancer predisposition gene.

This study reported that Malassezia-associated dermatitis can cause pruritus in cats with feline paraneoplastic alopecia.

In this case study, a man with necrolytic migratory erythema and a glucagonoma experienced decreased plasma glucagon levels and reduced metastases after treatment with dimethyltriazenoimidazole carboxamide.

The cat had liver cancer and a related hair loss condition, with a likely cause being bile duct cancer.

This report describes a paraneoplastic alopecia in four cats associated with internal malignancy, confirming previous findings of a syndrome linking ventral alopecia and metastatic carcinomas.

This case report described a rare combination of synchronous gallbladder and pancreatic cancers with an unusual initial symptom of complete loss of facial and scalp hair, marking a unique presentation never previously documented for abdominal malignancies in medical literature.

This case study of a cat with pancreatic carcinoma and paraneoplastic alopecia found that removing the internal tumor reversed hair loss, but symptoms reappeared as the cancer metastasized.

S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.

In this study, a validated chromatographic method demonstrated the ability to simultaneously analyze gemcitabine and olaparib in pancreatic cancer tissues, supporting the advancement of pharmaceutical formulations combining these drugs, particularly for patients with BRCA mutations.

In this qualitative study, researchers found that patients with metastatic pancreatic cancer frequently experience symptoms such as tiredness, nausea, and pain, as well as impacts like anxiety, leading to a revised conceptual model to improve patient-reported outcome measures in future clinical trials.

This study found that the K19 promoter is active in certain gastrointestinal cancer cells and its activity is influenced by the interaction between GKLF and Sp1 transcription factors.

This study identified high expression of the Sur2A subunit in cancerous cells in two animal models, highlighting a potential drug target in breast and renal cancers, with additional pharmacovigilance data linking KATP channel genes to varied cancer risks.

This study found that spironolactone enhanced the effectiveness of non-DNA-damaging cancer drugs gemcitabine and osimertinib in cancer cell lines and a mouse xenograft model, likely by suppressing the anti-apoptotic protein survivin.

This study highlighted Keratin 17's critical role in cancer therapy resistance across several malignancies, involving various signaling pathways, and identified it as a significant biomarker and potential therapeutic target, particularly in reversing resistance.

This review explores the complex, context-dependent roles of tumor-secreted proteins and suggests that some proteins traditionally seen as tumor-promotive may act as tumor-suppressors in different environments, emphasizing the influence of cell fitness and treatment exposure.

This study reported that palliative chemotherapy prolonged overall and quality-adjusted survival in patients with advanced gastric cancer, with improved quality of life compared to best supportive care, but increased costs.

This review discusses the benefits of β-sitosterol, a plant compound found in nuts and seeds, which may lower "bad" cholesterol and help prevent heart disease, cancer, and diabetes, but notes the lack of clinical studies on its safety and effectiveness in humans.

This chapter reviews the characteristics, diagnosis, and management of preneoplastic and paraneoplastic syndromes in small animals but does not present new clinical findings.

This conference proceeding abstract provides no new research results, focusing only on event details from the British Association of Dermatology's Forty-Sixth Annual Meeting held in Oxford in 1966.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

This review highlights recent literature on comorbidities in dermatologic diseases, emphasizing the need for further research into connections between atopic dermatitis and pancreatic cancer, and pemphigus diseases and COPD, but it reports no new clinical results.

This study found that KrasG12D mutant cells are typically cleared from adult pancreas tissues through mechanisms involving the EphA2 receptor, suggesting its role as a tumor suppressor in pancreatic cancer.